Cost‐effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola‐R‐CHP) in previously untreated diffuse large B‐cell lymphoma in Germany
Summary We evaluated the cost‐effectiveness of frontline polatuzumab vedotin‐R‐CHP (pola‐R‐CHP) treatment for patients with diffuse large B‐cell lymphoma (DLBCL) in Germany by using a Markov model (lifetime horizon). Progression rates and survival outcomes were extrapolated from the POLARIX trial. O...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2023-08, Vol.202 (4), p.771-775 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 775 |
|---|---|
| container_issue | 4 |
| container_start_page | 771 |
| container_title | British journal of haematology |
| container_volume | 202 |
| creator | Kambhampati, Swetha Shumilov, Evgenii Saumoy, Monica Herrera, Alex F. Tilly, Hervé Lenz, Georg Thiruvengadam, Nikhil R. |
| description | Summary
We evaluated the cost‐effectiveness of frontline polatuzumab vedotin‐R‐CHP (pola‐R‐CHP) treatment for patients with diffuse large B‐cell lymphoma (DLBCL) in Germany by using a Markov model (lifetime horizon). Progression rates and survival outcomes were extrapolated from the POLARIX trial. Outcomes were measured in incremental cost‐effectiveness ratios (ICERS) with a willingness‐to‐pay (WTP) threshold of €80 000/quality‐adjusted life‐years (QALY). Assuming, 69.6% 5‐year PFS with pola‐R‐CHP and 62.6% 5‐year PFS with R‐CHOP, the addition of polatuzumab vedotin resulted in an additional 0.52 life‐years and an incremental 0.65 QALYs but €31 988 additional cost. Based on this, pola‐R‐CHP was cost‐effective (€49 238/QALY) at a WTP of €80 000/QALY. The cost‐effectiveness of pola‐R‐CHP is highly dependent on its long‐term outcomes and cost. Our analysis is limited by the fact that the long‐term outcomes of pola‐R‐CHP are unknown at this time. |
| doi_str_mv | 10.1111/bjh.18869 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2814530230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2814530230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3889-e1199973e28f84c9f1e753fa916b35d1d1e3b66ef051bf13bd398d02d019a8d3</originalsourceid><addsrcrecordid>eNp1kcFu1DAURS0EokNhwQ8gS2zaRVq_OMk4SzqCDqgSCHUfOfEz41EcB9uZKl3xCXwFH8aX4DCFBRJPfvLm3Kurdwl5CewC0ly2-90FCFHVj8gKeFVmORTwmKwYY-sMWCFOyLMQ9owBZyU8JSd8nXBewor82LgQf377jlpjF80BBwyBOk1H18s43U9WtvSAykUz0PQ6Z1szyGjcQO9M3NFuh9YZa6fBxR16Oc70bNEmz89pN9tP54tu9Hgwbgr9TKchepQRFVVG6ykg7aX_gvQq4R32Pe1nO-6clYvuGr2Vw_ycPNGyD_ji4T8lt-_e3m622c3H6_ebNzdZx4WoMwSo63rNMRdaFF2tAdcl17KGquWlAgXI26pCnc7QauCt4rVQLFcMaikUPyVnR9vRu68ThthYE5ZMcsAUvskFFCVnOWcJff0PuneTH1K4RJVQFBUvq0SdH6nOuxA86mb0xko_N8Capbsmddf87i6xrx4cp9ai-kv-KSsBl0fgzvQ4_9-pufqwPVr-AsdxqcU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2851446356</pqid></control><display><type>article</type><title>Cost‐effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola‐R‐CHP) in previously untreated diffuse large B‐cell lymphoma in Germany</title><source>Wiley Free Content</source><source>Wiley Online Library All Journals</source><creator>Kambhampati, Swetha ; Shumilov, Evgenii ; Saumoy, Monica ; Herrera, Alex F. ; Tilly, Hervé ; Lenz, Georg ; Thiruvengadam, Nikhil R.</creator><creatorcontrib>Kambhampati, Swetha ; Shumilov, Evgenii ; Saumoy, Monica ; Herrera, Alex F. ; Tilly, Hervé ; Lenz, Georg ; Thiruvengadam, Nikhil R.</creatorcontrib><description>Summary
We evaluated the cost‐effectiveness of frontline polatuzumab vedotin‐R‐CHP (pola‐R‐CHP) treatment for patients with diffuse large B‐cell lymphoma (DLBCL) in Germany by using a Markov model (lifetime horizon). Progression rates and survival outcomes were extrapolated from the POLARIX trial. Outcomes were measured in incremental cost‐effectiveness ratios (ICERS) with a willingness‐to‐pay (WTP) threshold of €80 000/quality‐adjusted life‐years (QALY). Assuming, 69.6% 5‐year PFS with pola‐R‐CHP and 62.6% 5‐year PFS with R‐CHOP, the addition of polatuzumab vedotin resulted in an additional 0.52 life‐years and an incremental 0.65 QALYs but €31 988 additional cost. Based on this, pola‐R‐CHP was cost‐effective (€49 238/QALY) at a WTP of €80 000/QALY. The cost‐effectiveness of pola‐R‐CHP is highly dependent on its long‐term outcomes and cost. Our analysis is limited by the fact that the long‐term outcomes of pola‐R‐CHP are unknown at this time.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.18869</identifier><identifier>PMID: 37188351</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>B-cell lymphoma ; cost‐effectiveness analysis ; DLBCL ; Hematology ; lymphoma ; Markov chains ; pola‐R‐CHP ; R‐CHOP</subject><ispartof>British journal of haematology, 2023-08, Vol.202 (4), p.771-775</ispartof><rights>2023 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3889-e1199973e28f84c9f1e753fa916b35d1d1e3b66ef051bf13bd398d02d019a8d3</citedby><cites>FETCH-LOGICAL-c3889-e1199973e28f84c9f1e753fa916b35d1d1e3b66ef051bf13bd398d02d019a8d3</cites><orcidid>0000-0002-5776-3274 ; 0000-0002-9665-7415 ; 0000-0002-4728-1693</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.18869$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.18869$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,1433,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37188351$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kambhampati, Swetha</creatorcontrib><creatorcontrib>Shumilov, Evgenii</creatorcontrib><creatorcontrib>Saumoy, Monica</creatorcontrib><creatorcontrib>Herrera, Alex F.</creatorcontrib><creatorcontrib>Tilly, Hervé</creatorcontrib><creatorcontrib>Lenz, Georg</creatorcontrib><creatorcontrib>Thiruvengadam, Nikhil R.</creatorcontrib><title>Cost‐effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola‐R‐CHP) in previously untreated diffuse large B‐cell lymphoma in Germany</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
We evaluated the cost‐effectiveness of frontline polatuzumab vedotin‐R‐CHP (pola‐R‐CHP) treatment for patients with diffuse large B‐cell lymphoma (DLBCL) in Germany by using a Markov model (lifetime horizon). Progression rates and survival outcomes were extrapolated from the POLARIX trial. Outcomes were measured in incremental cost‐effectiveness ratios (ICERS) with a willingness‐to‐pay (WTP) threshold of €80 000/quality‐adjusted life‐years (QALY). Assuming, 69.6% 5‐year PFS with pola‐R‐CHP and 62.6% 5‐year PFS with R‐CHOP, the addition of polatuzumab vedotin resulted in an additional 0.52 life‐years and an incremental 0.65 QALYs but €31 988 additional cost. Based on this, pola‐R‐CHP was cost‐effective (€49 238/QALY) at a WTP of €80 000/QALY. The cost‐effectiveness of pola‐R‐CHP is highly dependent on its long‐term outcomes and cost. Our analysis is limited by the fact that the long‐term outcomes of pola‐R‐CHP are unknown at this time.</description><subject>B-cell lymphoma</subject><subject>cost‐effectiveness analysis</subject><subject>DLBCL</subject><subject>Hematology</subject><subject>lymphoma</subject><subject>Markov chains</subject><subject>pola‐R‐CHP</subject><subject>R‐CHOP</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kcFu1DAURS0EokNhwQ8gS2zaRVq_OMk4SzqCDqgSCHUfOfEz41EcB9uZKl3xCXwFH8aX4DCFBRJPfvLm3Kurdwl5CewC0ly2-90FCFHVj8gKeFVmORTwmKwYY-sMWCFOyLMQ9owBZyU8JSd8nXBewor82LgQf377jlpjF80BBwyBOk1H18s43U9WtvSAykUz0PQ6Z1szyGjcQO9M3NFuh9YZa6fBxR16Oc70bNEmz89pN9tP54tu9Hgwbgr9TKchepQRFVVG6ykg7aX_gvQq4R32Pe1nO-6clYvuGr2Vw_ycPNGyD_ji4T8lt-_e3m622c3H6_ebNzdZx4WoMwSo63rNMRdaFF2tAdcl17KGquWlAgXI26pCnc7QauCt4rVQLFcMaikUPyVnR9vRu68ThthYE5ZMcsAUvskFFCVnOWcJff0PuneTH1K4RJVQFBUvq0SdH6nOuxA86mb0xko_N8Capbsmddf87i6xrx4cp9ai-kv-KSsBl0fgzvQ4_9-pufqwPVr-AsdxqcU</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Kambhampati, Swetha</creator><creator>Shumilov, Evgenii</creator><creator>Saumoy, Monica</creator><creator>Herrera, Alex F.</creator><creator>Tilly, Hervé</creator><creator>Lenz, Georg</creator><creator>Thiruvengadam, Nikhil R.</creator><general>Blackwell Publishing Ltd</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5776-3274</orcidid><orcidid>https://orcid.org/0000-0002-9665-7415</orcidid><orcidid>https://orcid.org/0000-0002-4728-1693</orcidid></search><sort><creationdate>202308</creationdate><title>Cost‐effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola‐R‐CHP) in previously untreated diffuse large B‐cell lymphoma in Germany</title><author>Kambhampati, Swetha ; Shumilov, Evgenii ; Saumoy, Monica ; Herrera, Alex F. ; Tilly, Hervé ; Lenz, Georg ; Thiruvengadam, Nikhil R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3889-e1199973e28f84c9f1e753fa916b35d1d1e3b66ef051bf13bd398d02d019a8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>B-cell lymphoma</topic><topic>cost‐effectiveness analysis</topic><topic>DLBCL</topic><topic>Hematology</topic><topic>lymphoma</topic><topic>Markov chains</topic><topic>pola‐R‐CHP</topic><topic>R‐CHOP</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kambhampati, Swetha</creatorcontrib><creatorcontrib>Shumilov, Evgenii</creatorcontrib><creatorcontrib>Saumoy, Monica</creatorcontrib><creatorcontrib>Herrera, Alex F.</creatorcontrib><creatorcontrib>Tilly, Hervé</creatorcontrib><creatorcontrib>Lenz, Georg</creatorcontrib><creatorcontrib>Thiruvengadam, Nikhil R.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kambhampati, Swetha</au><au>Shumilov, Evgenii</au><au>Saumoy, Monica</au><au>Herrera, Alex F.</au><au>Tilly, Hervé</au><au>Lenz, Georg</au><au>Thiruvengadam, Nikhil R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost‐effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola‐R‐CHP) in previously untreated diffuse large B‐cell lymphoma in Germany</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2023-08</date><risdate>2023</risdate><volume>202</volume><issue>4</issue><spage>771</spage><epage>775</epage><pages>771-775</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
We evaluated the cost‐effectiveness of frontline polatuzumab vedotin‐R‐CHP (pola‐R‐CHP) treatment for patients with diffuse large B‐cell lymphoma (DLBCL) in Germany by using a Markov model (lifetime horizon). Progression rates and survival outcomes were extrapolated from the POLARIX trial. Outcomes were measured in incremental cost‐effectiveness ratios (ICERS) with a willingness‐to‐pay (WTP) threshold of €80 000/quality‐adjusted life‐years (QALY). Assuming, 69.6% 5‐year PFS with pola‐R‐CHP and 62.6% 5‐year PFS with R‐CHOP, the addition of polatuzumab vedotin resulted in an additional 0.52 life‐years and an incremental 0.65 QALYs but €31 988 additional cost. Based on this, pola‐R‐CHP was cost‐effective (€49 238/QALY) at a WTP of €80 000/QALY. The cost‐effectiveness of pola‐R‐CHP is highly dependent on its long‐term outcomes and cost. Our analysis is limited by the fact that the long‐term outcomes of pola‐R‐CHP are unknown at this time.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>37188351</pmid><doi>10.1111/bjh.18869</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-5776-3274</orcidid><orcidid>https://orcid.org/0000-0002-9665-7415</orcidid><orcidid>https://orcid.org/0000-0002-4728-1693</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2023-08, Vol.202 (4), p.771-775 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2814530230 |
| source | Wiley Free Content; Wiley Online Library All Journals |
| subjects | B-cell lymphoma cost‐effectiveness analysis DLBCL Hematology lymphoma Markov chains pola‐R‐CHP R‐CHOP |
| title | Cost‐effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola‐R‐CHP) in previously untreated diffuse large B‐cell lymphoma in Germany |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A52%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%E2%80%90effectiveness%20of%20polatuzumab%20vedotin%20in%20combination%20with%20chemoimmunotherapy%20(pola%E2%80%90R%E2%80%90CHP)%20in%20previously%20untreated%20diffuse%20large%20B%E2%80%90cell%20lymphoma%20in%20Germany&rft.jtitle=British%20journal%20of%20haematology&rft.au=Kambhampati,%20Swetha&rft.date=2023-08&rft.volume=202&rft.issue=4&rft.spage=771&rft.epage=775&rft.pages=771-775&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.18869&rft_dat=%3Cproquest_cross%3E2814530230%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2851446356&rft_id=info:pmid/37188351&rfr_iscdi=true |